Form 4: Ligand Pharmaceuticals Director Nancy Ryan Gray Receives Equity Grants

Ligand Pharmaceuticals Inc. Director Nancy Ryan Gray was granted 1,209 restricted stock units and 5,783 non-qualified stock options as part of her compensation, according to a recent SEC Form 4 filing.

Summary

• Nancy Ryan Gray, a Director at Ligand Pharmaceuticals Inc. (LGND), acquired 1,209 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 6, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock and was granted by the Board of Directors at their annual meeting.
• These RSUs fully vest on the earlier of the date of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date.
• Additionally, Ms. Gray was granted 5,783 non-qualified stock options on June 6, 2025, with an exercise price of $105.99 per share.
• These stock options also fully vest on the earlier of the date of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date, and expire on June 6, 2035.
• Following these transactions, Nancy Ryan Gray beneficially owns 8,094 shares of Common Stock directly and 5,783 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is a neutral to slightly positive event as it aligns the director's interests with shareholders. It does not contain any negative financial or operational news.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with long-term shareholder value.
• The equity grants serve as a form of compensation, indicating continued commitment of the director to the company.

Future Outlook

The document indicates future vesting of the granted restricted stock units and stock options, which will occur on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date.

Industry Context

This Form 4 filing is a routine disclosure of insider compensation in the form of equity grants, common practice across various industries, including the pharmaceutical sector, to incentivize long-term performance and align management interests with shareholders.

Comparison to Industry Standards

• The grant of RSUs and stock options to a director is a standard practice for executive and board compensation in publicly traded companies, including those in the biotechnology and pharmaceutical industries like Ligand Pharmaceuticals.
• The vesting schedule, tied to either the next annual meeting or the first anniversary of the grant, is typical for director equity compensation, aiming to retain and incentivize board members over a reasonable period.

Related Party Transactions

• The grant of restricted stock units and non-qualified stock options to Director Nancy Ryan Gray constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this filing, as it pertains to director compensation.

Next Steps

• The restricted stock units and stock options will vest on the earlier of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Ligand Pharmaceuticals, LGND, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership